Related Experiment Video
Updated: May 25, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy
Yoshiya Yamada1, Leland Rogers, D Jeffrey Demanes
1Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. yamadaj@mskcc.org
Brachytherapy
|January 24, 2012
Summary
High-dose-rate (HDR) brachytherapy offers excellent outcomes for localized prostate cancer, with high biochemical control rates and low toxicity. HDR monotherapy shows promise for both primary treatment and salvage.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- High-dose-rate (HDR) brachytherapy is established for localized prostate cancer.
- Literature often describes HDR as a boost with external beam radiation, but HDR monotherapy is increasingly used.
Purpose of the Study:
- To develop guidelines for HDR use in prostate cancer management.
- To consolidate expert opinion and literature review on HDR brachytherapy.
Main Methods:
- Convened expert practitioners and physicists from the American Brachytherapy Society.
- Conducted an extensive literature review.
- Incorporated input from an expert panel.
Main Results:
- HDR brachytherapy achieved biochemical control rates of 85-100% (low-risk), 81-100% (intermediate-risk), and 43-93% (high-risk).
- Severe toxicity (Grade 3 or higher) was rare, reported in less than 5% of cases.
- Successful treatment relies on patient selection, technique, planning, and delivery.
Conclusions:
- HDR brachytherapy demonstrates excellent clinical outcomes with high biochemical control and low morbidity.
- HDR monotherapy is a promising option for primary prostate cancer treatment and salvage therapy.
